Aktienanalyse zu SpyGlass Pharma Inc (SGP)

$26.420

-0.499 (-1.89%)Zum Schluss

Loading chart…

High: 27.100
Open: 27.000
VWAP: 26.51
Vol: 89.78K
Mkt Cap: —
Low: 26.000
Amount: 2.38M
EV/EBITDA, TTM: 0.00

SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

spyglasspharma.com

AI analysis of SpyGlass Pharma Inc (SGP)

buy

SpyGlass Pharma, Inc. (SGP) is a good buy right now, trading at $26.42 with a strong analyst price target of $42 from multiple firms, suggesting a potential upside of 58%. The RSI is at 55.14, indicating a neutral momentum, and the stock has shown a year-to-date change of +65.13%, reflecting strong investor interest. The main risk is the recent wider net loss of $19.9 million for Q2, which could impact short-term performance.

Bewertungskennzahlen

The current forward P/E ratio for SpyGlass Pharma Inc (SGP) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E

Current P/E

0.00

Forward EV/EBITDA

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Forward P/S

5Y Average P/S

Current P/S

0.00

Whales holding SGP

Vestal Point Capital, LP

+ HoldingSGP

+10.94%

3M Return

IOOF Investment Management Limited

+ HoldingSGP

+10.15%

3M Return

Mutual Trust Pty Ltd

+ HoldingSGP

+2.90%

3M Return

RA Capital Management, L.P.

+ HoldingSGP

+2.43%

3M Return

Event-Zeitleiste

2026-08-06 (ET)